La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
BARCELONA, Spain I March 10, 2026 I La Merie Publishing announced the publication of the biologics market report for the calendar year 2025 covering individual sales data for more than 400 biologic products. The report “2025 Sales of Therapeutic Antibodies,
MUC16: old target revisited with new technologies – a pipeline review STUTTGART, Germany I November 10, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research and development
CDH6: clinical PoC of lead anti-CDH6 ADC boosts pipeline – a pipeline review STUTTGART, Germany I November 08, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in research
MUC1: an old target accessed with new technologies leading to first signs of clinical activity – a pipeline review STUTTGART, Germany I November 06, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline
Claudin 18.2: a clinically validated target and plenty of improvement options with new drug modalities – a pipeline review STUTTGART, Germany I September 25, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline
PD-L1 and 4-1BB (CD137): promising immuno-oncology therapy combination to overcome on-target-off-tumor toxicity – a pipeline review STUTTGART, Germany I September 24, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy
CD47 and SIRPα: next generation inhibitors to show clinical benefit – a pipeline review STUTTGART, Germany I September 23, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active therapy candidates in
Complement C5: a commercially successful and clinically effective treatment of C5 mediated diseases – a pipeline review STUTTGART, Germany I September 22, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active
IL-6 and IL-6R: hot targets for underexploited indications – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active IL-6R antagonists and IL-6 inhibitors
CD40 and CD40L: a versatile target as co-stimulator in cancer and for antagonism in autoimmune diseases – a pipeline review STUTTGART, Germany I September 09, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the
